PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M

Stock Information for PhaseBio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About PhaseBio Pharmaceuticals Inc.

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code
PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab
PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights
PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference
PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab
PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights
PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.